CCCC 8-K 2026-11-05

C4 Therapeutics, Inc. (CCCC) 8-K dated 2026-11-05 — accession 0001628280-26-070560.

C4 Therapeutics, Inc. (CCCC) is a biotechnology company listed on US.

CCCC: EX-99.1 2 exhibit991q32026earnings.htm EX-99.1 1 C4 Therapeutics Report…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported CCCC revenue for 2025-12-31 was $35.9M. Net income was -$105.0M. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. CCCC currently screens at market cap $425.7M.

Not investment advice. The CCCC SEC hub lists recent forms. The stock page is the research view.